⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15008003 | 0.97 | — | — | |
| SCHEMBL17797679 | 0.97 | CHEK1 (0.34) | — | |
| SCHEMBL16877599 | 0.97 | CHEK1 (0.34) | — | |
| SCHEMBL746781 | 0.97 | CHEK1 (0.36) | — | |
| Hydrochloric Acid SCHEMBL22394950 | 0.94 | CHEK1 (0.33) | — | |
| SCHEMBL25229684 | 0.93 | CHEK1 (0.35) | — | |
| SCHEMBL20104746 | 0.93 | CHEK1 (0.35) | — | |
| SCHEMBL25231616 | 0.93 | CHEK1 (0.35) | — | |
| SCHEMBL21573995 | 0.93 | CHEK1 (0.35) | — | |
| SCHEMBL1828890 | 0.93 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 437 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4308576-B1 | NEW THIAZOLOPYRIMIDINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2025-04-23 | — | — | EP | claimed |
| EP-4308572-B1 | NEW THIENOPYRIMIDINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2025-04-23 | — | — | EP | claimed |
| EP-4308577-B1 | NEW THIADIAZOLOPYRIMIDONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2024-12-25 | — | — | EP | claimed |
| CN-118791418-A | Indole compound and preparation method and application thereof | 纽欧申医药(上海)有限公司 | 2024-10-18 | — | — | CN | claimed |
| WO-2024213032-A1 | INDOLE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 纽欧申医药(上海)有限公司 | 2024-10-17 | — | — | WO | claimed |
| EP-4308576-A1 | NEW THIAZOLOPYRIMIDINONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2024-01-24 | — | — | EP | claimed |
| WO-2023159322-A1 | QUINAZOLINE DERIVATIVES AS INHIBITORS OF THE GCN2 KINASE, COMPOSITIONS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2023-08-31 | — | — | WO | claimed |
| WO-2022194801-A1 | NEW THIAZOLOPYRIMIDINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2022-09-22 | — | — | WO | claimed |
| WO-2019217822-A1 | COMPOUNDS AND METHODS OF USING COMPOUNDS FOR THE PREVENTION OR TREATMENT OF INFLAMMATORY CONDITIONS | CHROMOCELL CORPORATION (US) | 2019-11-14 | — | — | WO | claimed |
| US-10364256-B2 | Biaryl pyrazoles as NRF2 regulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-30 | — | — | US | claimed |
| US-10351530-B2 | Arylcyclohexyl pyrazoles as NRF2 regulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-16 | — | — | US | claimed |
| US-20180282283-A1 | ARYLCYCLOHEXYL PYRAZOLES AS NRF2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2018-10-04 | — | — | US | claimed |
| US-20180282349-A1 | BIARYL PYRAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-10-04 | — | — | US | claimed |
| EP-3371167-A1 | ARYLCYCLOHEXYL PYRAZOLES AS NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-09-12 | — | — | EP | claimed |
| EP-3193610-A1 | SELECTIVE NAV1.7 INHIBITORS FOR THE TREATMENT OF DIABETES | Chromocell Corporation (US) | 2017-07-26 | — | — | EP | claimed |
| WO-2017060854-A1 | BIARYL PYRAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-04-13 | — | — | WO | claimed |
| WO-2017060855-A1 | ARYLCYCLOHEXYL PYRAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-04-13 | — | — | WO | claimed |
| WO-2016040315-A1 | SELECTIVE NAV1.7 INHIBITORS FOR THE TREATMENT OF DIABETES | CHROMOCELL CORPORATION (US) | 2016-03-17 | — | — | WO | claimed |
| WO-2026107349-A1 | HETEROCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASES | ANTARES THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-4287199-A | USEFUL AS ANTHELMINITICS | BAYER AKTIENGESELLSCHAFT (DE) | 1981-09-01 | — | — | US | disclosed |